About us
We’re going nuclear on cancer
And we’re backing it up. Our extensive preclinical and clinical data are leading the field and inspiring confidence in our approach to treating cancers, including metastatic castration-resistant prostate cancer (mCRPC).
Fiercely guided
by our values
BE TRANSFORMATIVE
Envision a better future for patients.
BE VERSATILE
Tirelessly seek the best solutions through teamwork, innovation, and flexibility.
BE PRECISE
Maintain our focus on the task at hand, recognizing that details matter.
An undeniable commitment to
patients shaped by our legacy
Dr. Philip Kantoff
World-renowned medical oncologist and scientist
Prior to joining Convergent Therapeutics, Dr. Kantoff spent six years as Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center, where he directed a department of approximately 500 physicians and physician-scientists, caring for cancer patients and developing biomarkers and cancer therapies.
He is the Emeritus Jerome and Nancy Kohlberg Chair in Medicine at Harvard Medical School. At the Dana-Farber Cancer Institute (DFCI), he was the Chief of the Solid Tumor Oncology Division, and he served as Director of the Lank Center for Genitourinary Oncology. In those positions, Dr. Kantoff created robust programs of clinical care and research as well as laboratory research. During this time, he served as a clinical researcher and principal investigator in significant trials devoted to the development of new therapeutic targets for men with advanced prostate cancer and, throughout his tenure at DFCI, he helped to set broad clinical research priorities.
Dr. Kantoff is a member of numerous professional societies and editorial boards, has written more than 500 articles and books, and has lectured throughout the world. Among his significant accomplishments, Dr. Kantoff was honored with the Baruj Benacerraf Clinical Investigator Award from 1994 to 1997 and the Harvard Medical School Kantoff-Sang Lectureship Award from 2011 through the present time. He was also recognized with the first Prostate Cancer Foundation Mentor of Excellence Award, the second-year class of “Giants in Cancer Care” and the 2024 ASCO Excellence in Teaching Award. He was inducted into the Association of American Physicians in 2017. Dr. Kantoff is board certified in internal medicine and medical oncology. He completed his research fellowship at the National Institutes of Health and his medical oncology fellowship at the DFCI.
Dr. Neil Bander
A pioneer in radioantibody technology and the PSMA field
Dr. Neil H. Bander is the former Bernard and Josephine Chaus Professor of Urologic Oncology and current Professor Emeritus of Urology at Weill Cornell Medicine. While at Weill Cornell, his group developed the first series of monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could bind to viable PSMA-positive cells. These antibodies enabled them to define much of the biology of PSMA, successfully target prostate cancers in patients, and demonstrate the initial clinical validation of PSMA as a target in prostate and other cancers. As a result of the Bander team’s pioneering efforts over the past 25+ years, PSMA has become a target of enormous interest and activity in biotech and pharma.
Dr. Bander is a surgeon-scientist trained in urological oncology and tumor immunology, both at Memorial Sloan Kettering Cancer Center. He has authored more than 200 publications, and he is an inventor on approximately 150 US- and foreign-issued and pending patents. He has served on, and chaired, multiple grant study sections and review panels and received several honors, including the FC Valentine Fellowship from the NY Academy of Medicine, the Society of Surgical Oncology James Ewing Research Award, awards from the German and Japanese Urology Societies, the Prostate Cancer Foundation, and the Clark Medal for Surgical Innovation from the Royal College of Surgeons (London). He has served on several industry scientific advisory boards.
Alex Brown, MBA
A successful track record of leadership in operations and commercialization
Prior to joining Convergent, Mr. Brown was the Head of New Product Planning, Global Oncology, at Sanofi and was responsible for the commercial readiness of the company’s early-stage oncology pipeline. Before that, he served in several positions of increasing responsibility at EMD Serono (a Merck KGaA subsidiary). Mr. Brown was a founding member of the Merck KGaA-Pfizer immune-oncology alliance and responsible for the first commercialization of BAVENCIO® (avelumab) in Merkle cell carcinoma. Earlier in his career, Mr. Brown supported the commercialization of ICLUSIG® (ponatinib) and ALUNBRIG® (brigatinib) at ARIAD Pharmaceuticals, and earlier at Sanofi, was responsible for global development operations in support of the launch and life-cycle management of JEVTANA® (cabazitaxel) in prostate cancer.
Mr. Brown earned his Bachelor of Science in medical microbiology and immunology from the University of Wisconsin-Madison and his Master of Business Administration from Carnegie Mellon University.
Richard Messmann, MD, MHS, MSc
Proven leadership in the development of radiopharmaceuticals
Dr. Richard Messmann is a medical oncologist, clinical research physician, and biochemist with more than 25 years of experience in oncology drug development, including responsibility for the global clinical development and successful regulatory submission of PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) and LOCAMETZ® (gallium Ga 68 gozetotide) for the treatment of men with PSMA-expressing, metastatic castrate-resistant prostate cancer.
After residencies in internal medicine (Michigan State University) and anesthesiology/critical care (Georgetown University/University of Michigan), he completed fellowship training in medical oncology at the National Cancer Institute in Bethesda, Maryland, becoming the deputy associate director of the NIH/NCI’s Developmental Therapeutics Program (DTP) where he was in the inaugural class of the NIH-Duke Master’s Program in Clinical Research. During this time, he also served as a commissioned officer in the Public Health Service.
He has held leadership positions at Fusion Pharmaceuticals, Amgen, Novartis, Advanced Accelerator Applications (a subsidiary of Novartis), Endocyte, Eli Lilly & Co., Michigan State University, ProNAi Therapeutics, Apexian Pharmaceuticals, and Ocuphire Pharma.
Immediately prior to joining Convergent, he was the Senior Vice President and clinical lead for Fusion’s development of the actinium radiotherapeutic FPI-2265. While at Amgen, he was the Executive Medical Director and global program lead for the development of xaluritamig (AMG 509), an anti-STEAP1 XmAb 2+1 T-cell redirecting immune therapy for prostate cancer.
Eric M. Sullivan, CPA
Experienced leadership in both private and public biopharma ventures
Mr. Sullivan brings to Convergent more than 20 years of finance and operations experience in the biotechnology industry working on financial management, strategic planning, and fundraising and capital market transactions across the public and private markets. Prior to joining Convergent, he was Chief Financial Officer at TCR2 Therapeutics through the completion of the acquisition by Adaptimmune Therapeutics. Before that he was President, Chief Financial Officer and Chief Operations Officer at Triplet Therapeutics where he led finance, business development, and corporate operations. Earlier in his career he held senior management positions at Gemini Therapeutics, Oncorus, bluebird bio, Merrimack Pharmaceuticals, and PwC. Mr. Sullivan holds a Bachelor of Science in Accountancy from Bentley University and is a Certified Public Accountant.
Philip Kantoff, MD
Prior to joining Convergent, Dr. Kantoff spent six years as Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center, where he directed a department of approximately 500 physicians and physician-scientists, caring for cancer patients and developing improved testing and cancer therapies.
He is the Emeritus Jerome and Nancy Kohlberg Chair in Medicine at Harvard Medical School. At Dana Farber Cancer Institute (DFCI), he was the Chief of the Solid Tumor Oncology Division, and he served as Director of the Lank Center for Genitourinary Oncology at the DFCI. In those positions, Dr. Kantoff created robust programs of clinical care and research as well as laboratory research. During this time, he served as a clinical researcher and principal investigator in significant trials devoted to the development of new therapeutic targets for men with advanced prostate cancer and, throughout his tenure at DFCI, he helped to set broad clinical research priorities.
Dr. Kantoff is a member of numerous professional societies and editorial boards, has written more than 500 articles and books, and has lectured throughout the world. Among his significant accomplishments, Dr. Kantoff was honored with the Baruj Benacerraf Clinical Investigator Award from 1994 to 1997 and the Harvard Medical School Kantoff-Sang Lectureship Award from 2011 through the present time. He was also recognized with the first Prostate Cancer Foundation Mentor of Excellence Award and has been named to the second-year class of “Giants in Cancer Care.” He was inducted into the Association of American Physicians in 2017. Dr. Kantoff is board certified in internal medicine and medical oncology. He completed his research fellowship at the National Institutes of Health and his medical oncology fellowship at the DFCI.
Scott Myers, MBA
Mr. Myers has been a member of the Convergent board since May 2024. Mr. Myers has worked in the global pharmaceutical and medical technology industries for nearly three decades. Previously, he was the President and Chief Executive Officer and served on the board of directors of AMAG Pharmaceuticals, Inc., where he led its turnaround and strategic sale to Covis Pharma, S.à.r.l., a pharmaceutical company, in November 2020. Mr. Myers has served as Chairman of the board of directors of Rainier Therapeutics, Inc., an oncology biotechnology company focused on late-stage bladder cancer, from June 2018 to January 2020, and served as its Chief Executive Officer from September 2018 to January 2020. Mr. Myers led Rainier’s asset sale of vofatamab to Fusion Pharmaceuticals Inc. Prior to Rainier, Mr. Myers served as Chief Executive Officer, President and Director for Cascadian Therapeutics, Inc., an oncology company, from April 2016 through its acquisition by Seattle Genetics in March 2018. Mr. Myers was also President and CEO of Viridian Therapeutics and Aerocrine. In addition, he has held additional board and executive leadership roles at other biotechnology, pharmaceutical, and medtech companies. Mr. Myers currently chairs the boards of directors for Umoja Biopharma, Zentalis Pharmaceuticals, and Dynavax Technologies. He previously chaired the boards of directors for Ironshore until its acquisition by Collegium Pharmaceuticals and Harpoon Therapeutics until its acquisition by Merck, both in 2024. Mr. Myers holds an MBA in finance from the University of Chicago’s Graduate School of Business (Booth) and a Bachelor of Arts in Biology from Northwestern University.
Barbara Duncan, MBA
Ms. Duncan has been a member of the Convergent board since December 2024. Ms. Duncan brings more than 16 years of pharmaceutical and biotechnology industry experience to Convergent’s Board of Directors. She retired from Intercept Pharmaceuticals, Inc., a biopharmaceutical company, where she served as Chief Financial Officer and Treasurer from May 2009 to June 2016 and helped lead the operational and strategic plans, including managing the buildout of international operations and preparing financial teams for commercial product launch. From 2001 to 2009, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., a biotechnology company, including Chief Financial Officer and ultimately serving as Chief Executive Officer prior to DOV’s sale in 2010 to Euthymics Bioscience, Inc. At DOV, she developed and led in the execution of strategic plans, restructured several of the company’s partnerships and led negotiations on licensing transactions. Prior, Ms. Duncan served as Vice President of Corporate Finance - Global Healthcare at Lehman Brothers Inc. from 1998 to 2001, and as Director of Corporate Finance at SBC Warburg Dillon Read Inc. from 1994 to 1998. She also worked for PepsiCo, Inc. from 1989 to 1992 in its international audit division, and was a certified public accountant in the audit division of Deloitte & Touche LLP from 1986 to 1989.
Ms. Duncan received her Bachelor of Business Administration from Louisiana State University and her Master of Business Administration from the Wharton School of the University of Pennsylvania.
Jim Trenkle, PhD
Jim Trenkle is a Partner on the Venture Investments team at Novo Holdings and has been a member of the Convergent board since September 2024. Dr. Trenkle brings a background in R&D, commercialization, and early-stage biotech investing and transactions. Prior to joining Novo Holdings, Dr. Trenkle was Head of Investments at Sanofi Ventures in Cambridge, MA, where he was responsible for a team making investments into private US-based therapeutics life science companies. Prior to Sanofi, Dr. Trenkle was Vice President of Investments with Pivotal bioVenture Partners in San Francisco. Dr. Trenkle began his career with Gilead Sciences where he held positions of increasing responsibility in medicinal chemistry, project and portfolio management, and commercial strategy, largely focused on hepatitis C and other liver diseases.
Dr. Trenkle completed a Bachelor of Science in honors chemistry at University of Michigan, a PhD in organic chemistry at Massachusetts Institute of Technology and holds a Masters in Business Administration from University of California Berkeley, Haas School of Business.
Jake Simson, PhD
Dr. Simson has been a member of the Convergent board since May 2023. Dr. Simson is a Partner at RA Capital Management. He works on both public and private investments and serves as a Board Director for Janux Therapeutics, Tyra Biosciences, Bicara Therapeutics, Convergent Therapeutics, Septerna, and Outpace Bio. Previously, he covered solid tumor oncology landscapes.
Dr. Simson holds a Bachelor of Science in materials science and engineering from Massachusetts Institute of Technology and a PhD in biomedical engineering from Johns Hopkins University. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels.
Tal Zaks, MD, PhD
Tal Zaks, MD, PhD has been a member of the Convergent board since May 2023. Dr. Zaks is a partner at OrbiMed Advisors LLC since November 2021. From 2015 to September 2021, he served as Chief Medical Officer of Moderna, Inc. From 2010 to 2015, he held senior development positions at Sanofi, including Senior Vice President and Head of Global Oncology. From 2008 to 2010, he served as Vice President of Clinical Research, Oncology at Cephalon. From 2004 to 2008, he served as Director, Clinical Development and Translational Medicine at GlaxoSmithKline. From 1996 to 1999, he was a Postdoctoral Fellow at the National Cancer Institute. Dr. Zaks has also served as an adjunct Associate Professor of Medicine at the University of Pennsylvania since 2004.
Dr. Zaks received his MD and PhD from Ben-Gurion University in Israel, conducted postdoctoral research at the US National Institutes of Health and completed clinical training in internal medicine at Temple University Hospital, followed by a fellowship in medical oncology at the University of Pennsylvania. He has also been awarded PhD honoris causa from Bar-Ilan University.
Neil Bander, MD
Dr. Neil H. Bander is the former Bernard and Josephine Chaus Professor of Urologic Oncology and current Professor Emeritus of Urology at Weill Cornell Medicine. While at Weill Cornell, his group developed the first monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could successfully target prostate cancers in patients. This enabled them to define much of the biology of PSMA and clinically validate PSMA as a target in prostate and other cancers. As a result of Dr. Bander and his team’s pioneering efforts, PSMA has become a target of substantial interest and activity in bio-pharma.
Dr. Bander is a surgeon-scientist trained in urological oncology and tumor immunology, both at Memorial Sloan Kettering Cancer Center. He has authored more than 200 peer-reviewed publications, and he is an inventor on approximately 150 US- and foreign-issued and pending patents. He has served on, and chaired, multiple study sections and grant review panels and received several honors, including the FC Valentine Fellowship from the NY Academy of Medicine, the Society of Surgical Oncology James Ewing Research Award, awards from the German and Japanese Urology Societies, the Prostate Cancer Foundation, and the Clark Medal for Surgical Innovation from the Royal College of Surgeons (London). He also serves on several industry scientific advisory boards.
Company investors
Discover the potential
of radioantibodies
Our technology is already making a difference
to patients with cancer.
